InvestorsHub Logo
Followers 230
Posts 21489
Boards Moderated 2
Alias Born 08/03/2006

Re: None

Wednesday, 11/16/2022 10:50:26 AM

Wednesday, November 16, 2022 10:50:26 AM

Post# of 9772
"We expect to submit our new drug application (NDA) application to the FDA for HyBryte(TM) during this quarter. Additionally, we are continuing our expansion into new disease indications with synthetic hypericin having received FDA investigational new drug (IND) clearance for a Phase 2a clinical trial in mild-to-moderate psoriasis, also expected to begin before year end.


https://finance.yahoo.com/news/soligenix-inc-showcase-2022-milestones-120000272.html


Do your research! Play the TA. All posts are my opinion.
Is fundamental trading dead?

"We hope not." Richard Dennis

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SNGX News